Видео ютуба по тегу Undetectable Mrd

Dr Burke on MRD Testing in CLL and Myeloma
Dr Burke on MRD Testing in CLL and Myeloma
Analysis of GAIA/CLL13: the role of NGS-based MRD assessment after ven-based 1L combinations for CLL
Analysis of GAIA/CLL13: the role of NGS-based MRD assessment after ven-based 1L combinations for CLL
MRD-Guided Venetoclax Plus Obinutuzumab Therapy for CLL - Dr. Meghan Thompson
MRD-Guided Venetoclax Plus Obinutuzumab Therapy for CLL - Dr. Meghan Thompson
Undetectable Measurable Residual Disease in CLL / SLL - Dr. Tilal Hilal
Undetectable Measurable Residual Disease in CLL / SLL - Dr. Tilal Hilal
Driver mutations predicting clinical outcomes upon MRD-guided venetoclax plus ibrutinib in R/R CLL
Driver mutations predicting clinical outcomes upon MRD-guided venetoclax plus ibrutinib in R/R CLL
Barriers to the implementation of MRD-guided treatment into CLL clinical practice
Barriers to the implementation of MRD-guided treatment into CLL clinical practice
The Role of MRD in Guiding Treatment for CLL - Dr. Peter Hillmen ASH 2023
The Role of MRD in Guiding Treatment for CLL - Dr. Peter Hillmen ASH 2023
Adding Venetoclax to Ibrutinib for CLL Patients with High-Risk Disease - Dr. Bill Wierda ASH 2021
Adding Venetoclax to Ibrutinib for CLL Patients with High-Risk Disease - Dr. Bill Wierda ASH 2021
Post-induction undetectable MRD ameliorates the high risk determined by FISH among NDMM
Post-induction undetectable MRD ameliorates the high risk determined by FISH among NDMM
Future research into MRD-guided treatment of CLL
Future research into MRD-guided treatment of CLL
BOVen regimen for previously untreated CLL: long-term follow-up and MRD kinetics
BOVen regimen for previously untreated CLL: long-term follow-up and MRD kinetics
Multiomics Profiling of MRD for Understanding the Biology of Ultra-Drug Resistance in Myeloma
Multiomics Profiling of MRD for Understanding the Biology of Ultra-Drug Resistance in Myeloma
GEM-CESAR trial: post-hoc analysis of sustained undetectable MRD in patients with high-risk SMM
GEM-CESAR trial: post-hoc analysis of sustained undetectable MRD in patients with high-risk SMM
The impact of sustained undetectable MRD on survival in patients with myeloma treated with ide-cel
The impact of sustained undetectable MRD on survival in patients with myeloma treated with ide-cel
Curative Strategy for High-Risk Smoldering Myeloma: Post-Hoc Analysis of Sustained Undetectable MRD
Curative Strategy for High-Risk Smoldering Myeloma: Post-Hoc Analysis of Sustained Undetectable MRD
ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patients
ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patients
Pros and cons of MRD testing in CLL
Pros and cons of MRD testing in CLL
HOVON 141/VISION: MRD guided time-limited treatment in CLL
HOVON 141/VISION: MRD guided time-limited treatment in CLL
Predicting MRD outcomes in myeloma using machine learning
Predicting MRD outcomes in myeloma using machine learning
MRD monitoring in CLL and implications for clinical practice
MRD monitoring in CLL and implications for clinical practice
MRD negativity and response in AL amyloidosis
MRD negativity and response in AL amyloidosis
Exploring treatment resistance in myeloma with MRD
Exploring treatment resistance in myeloma with MRD
Achieving undetectable MRD with ibrutinib plus venetoclax for CLL
Achieving undetectable MRD with ibrutinib plus venetoclax for CLL
Prognostic importance of MRD: results of TOURMALINE-MM4 trial for NDMM
Prognostic importance of MRD: results of TOURMALINE-MM4 trial for NDMM
The assets of MRD in myeloma
The assets of MRD in myeloma